Bevacizumab-Based Therapies in Malignant Tumors-Real-World Data on Effectiveness, Safety, and Cost.
Elena ChitoranVlad RotaruSinziana-Octavia IonescuAisa GelalCristina-Mirela CapsaRoxana-Elena BohilteaMadalina-Nicoleta MitroiuDragoș ȘerbanGiuseppe GulloDaniela-Cristina StefanLaurentiu SimionPublished in: Cancers (2024)
Bevacizumab remains a high-cost therapy, but it can add to clinical benefits (like overall survival, progression-free survival, and response rate) when used in conjunction with standard chemotherapy. Similar results as those presented in various controlled trials are observable even on unselected cohorts of patients in the uncontrolled conditions of "real-world" oncological practice. Off-label usage is encountered in clinical practice, and this aspect should be monitored given the potential adverse effects of the therapy.
Keyphrases
- patient reported outcomes
- free survival
- clinical practice
- randomized controlled trial
- primary care
- systematic review
- end stage renal disease
- metastatic colorectal cancer
- chronic kidney disease
- locally advanced
- emergency department
- stem cells
- rectal cancer
- radiation therapy
- electronic health record
- squamous cell carcinoma
- ejection fraction
- newly diagnosed
- cell therapy
- peritoneal dialysis
- human health
- risk assessment
- quality improvement
- prognostic factors
- robot assisted
- replacement therapy
- drug induced